FK614 has been used in trials studying the treatment of Diabetes Mellitus. ATX08-001 is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include ATx08-001 and V5Q32BZX79. Its PubChem CID is 9869229.
Fk 614
| CAS No | 193012-35-0 |
|---|---|
| Molecular Formula | C21H23Cl2N3O3S |
| Molecular Weight | 468.40 g/mol |
| Synonyms | 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
FK614 has been used in trials studying the treatment of Diabetes Mellitus. ATX08-001 is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
The listed CAS number is 193012-35-0.
The listed molecular formula is C21H23Cl2N3O3S.
The listed molecular weight is 468.40 g/mol.
3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide.
The source lists ATx08-001 and V5Q32BZX79.